Drugs / SAR445514
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05839626 | May 2023 → May 2025 | AL amyloidosis, refractory plasma cell neoplasm | Sanofi | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAR445514 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05839626 ↗ |
| Route | Subcutaneous | “SAR445514 will be administered to participants with relapsed/refractory multiple myeloma (RRMM) using subcutaneous route (SC)” NCT05839626 ↗ |